Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: "Bench-to-bedside review: Understanding the impact of resistance and virulence factors on methicillin-resistant Staphylococcus aureus infections in the intensive care unit"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Bench-to-bedside review: Understanding the impact of resistance and virulence factors on methicillin-resistant Staphylococcus aureus infections in the intensive care unit. | Available online http ccforum.eom content 13 5 222 Review Bench-to-bedside review Understanding the impact of resistance and virulence factors on methicillin-resistant Staphylococcus aureus infections in the intensive care unit Lee P Skrupky1 Scott T Micek1 and Marin H Kollef2 1 Department of Pharmacy Barnes-Jewish Hospital St Louis MO 63110 USA 2Department of Pulmonary and Critical Care Medicine Washington University School of Medicine St Louis MO 63110 USA Corresponding author Marin H Kollef mkollef@dom.wustl.edu Published 8 October 2009 This article is online at http ccforum.com content 13 5 222 2009 BioMed Central Ltd Critical Care 2009 13 222 doi 10.1186 cc8028 Abstract Methicillin-resistant Staphylococcus aureus MRSA displays a remarkable array of resistance and virulence factors which have contributed to its prominent role in infections of the critically ill. We are beginning to understand the function and regulation of some of these factors and efforts are ongoing to better characterize the complex interplay between the microorganism and host response. It is important that clinicians recognize the changing resistance patterns and epidemiology of Staphylococcus spp. as these factors may impact patient outcomes. Community-associated MRSA clones have emerged as an increasingly important subset of Staphyloccocus aureus and MRSA can no longer be considered as solely a nosocomial pathogen. When initiating empiric antibiotics it is of vital importance that this therapy be timely and appropriate as delays in treatment are associated with adverse outcomes. Although vancomycin has long been considered a first-line therapy for serious MRSA infections multiple concerns with this agent have opened the door for existing and investigational agents demonstrating efficacy in this role. Methicillin-resistant Staphylococcus aureus MRSA has proven to be a prominent pathogen in the ICU setting capable of causing a variety of severe infections. In the face of increasing .